Article Details
Retrieved on: 2021-03-26 12:56:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The Phase II clinical trial of the combination therapy of ALK-1 monoclonal antibody and nivolumab for the second line therapy of HCC has been ...
Article found on: www.prnewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here